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Abstract 3 
Abstract 
 
Although there have been several previous reports of immunohistochemical staining 
for MHC antigens in muscle biopsies, there appears to be a lack of consensus about its 
routine use in the diagnostic evaluation of biopsies from patients with suspected 
inflammatory myopathy.  Positive MHC-I staining is nonspecific but is widely used as a 
marker for inflammatory myopathy, while the role of MHC-II staining is not clearly 
defined. We investigated the sensitivity and specificity of MHC-I and II immunostaining 
for the diagnosis of inflammatory myopathy in a large group of biopsies from a single 
reference laboratory.  Positive staining for MHC-I was found to have a high sensitivity 
in biopsies from patients with inflammatory myopathy but a very low specificity, as it 
was also common in other non-inflammatory myopathies and neurogenic disorders.  
On the other hand, MHC-II positivity had a much higher specificity in all major 
subgroups of inflammatory myopathy, especially inclusion body myositis.  The findings 
indicate that the combination of MHC-I and MHC-II staining results in a higher degree 
of specificity for the diagnosis of inflammatory myopathy and that in biopsies with 
inflammation, positive MHC-II staining strongly supports the diagnosis of an immune-
mediated myopathy. We recommend that immunohistochemical staining for both 
MHC-I and MHC-II should be included routinely in the diagnostic evaluation of muscle 
biopsies from patients with suspected inflammatory myopathy. However, as the 
sensitivity and interpretation of MHC staining may depend on the technique used, 
further studies are needed to compare procedures in different centres and develop 
standardised protocols. 
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1. Introduction 
 
As patients with idiopathic inflammatory myopathies (IIM) may benefit from immune 
therapies it is crucial to develop diagnostic tools that achieve a high level of sensitivity 
and specificity. Sets of diagnostic criteria for different types of IIM, based on a 
combination of clinical and pathological findings, have been proposed for use in clinical 
trials and research studies [1,2]. However, muscle biopsy is still the definitive 
diagnostic procedure in clinical practice and should ideally be performed before 
starting treatment [3]. A major concern is that as the pathology is often patchy the 
biopsy may not show an inflammatory infiltrate although it may be present in other 
parts of the muscle.  This is a well-known pitfall, especially when the biopsy is 
performed after treatment has been initiated [4]. In addition, inflammatory infiltrates 
are nonspecific and may also occur in other myopathies such as dysferlinopathy, 
facioscapulohumeral dystrophy and other types of muscular dystrophy and 
myasthenia gravis, and may lead to a mistaken diagnosis of an IIM [5,6]. Other markers 
of an autoimmune process are therefore necessary to improve the sensitivity and 
specificity of the muscle biopsy. Vascular membrane attack complex (MAC) and 
immunoglobulin deposition, and upregulation of major histocompatibility complex 
(MHC) antigens have been proposed as diagnostic criteria for IIM [2]. A number of 
previous studies, which have been summarised in Tables 1 and 2, have reported 
positive immunohistochemical staining for MHC in IIM and other muscle conditions. 
Some studies have also addressed the diagnostic value of MHC expression with 
different methodologies and results [7–9].  
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MHC-I is expressed but is undetectable immunohistochemically in normal muscle 
fibres and is up-regulated in IIM. MHC-I molecules are necessary for antigen-specific T 
cell-mediated cytotoxicity and can mediate a response against surface antigens on 
myofibres [10]. Previous studies have also shown that MHC-I can behave as a 
pathogenic molecule in its own right since its expression can precede lymphocytic cell 
infiltration, and transgenic mice overexpressing MHC-I have been shown to develop a 
severe myopathy even in the absence of inflammation [11–14]. Unlike the 
inflammatory infiltrates, MHC-I expression is still detectable even after short-term 
immunosuppressive treatment and in patients with chronic myositis [9,15]. Moreover, 
MHC-I staining often occurs early, preceding the inflammatory infiltrates, and is 
present diffusely throughout the biopsy and is thus less likely to be affected by 
sampling error [16]. Nevertheless, even though it has been considered helpful in 
distinguishing IIM from other muscle diseases, it is not specific and also occurs in other 
myopathies [17]. On the other hand, MHC-II expression does not occur constitutively 
on normal mature muscle fibres, unlike myoblasts in culture which express MHC-II and 
can behave as antigen-presenting cells [18,19]. Few studies have addressed the 
diagnostic value of MHC-II expression in IIM and the results of previous studies have 
varied (Table 1 and 2).  
 
In the present study we analysed the sensitivity and specificity of 
immunohistochemical staining for MHC-I and MHC-II in the diagnosis of IIM in a large 
group of muscle biopsies from a single reference centre. We paid particular attention 
to the contribution of MHC-II staining in improving diagnostic accuracy, as, in our 
experience, positive MHC-I staining alone is nonspecific.     
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2. Materials and methods 
 
2.1 Details of cases included  
We carried out a prospective survey of diagnostic muscle biopsies from 2000-2013 
referred to the Section of Neuropathology at Royal Perth Hospital, which is the State 
Reference Centre for muscle biopsies and the in-vitro contracture test (IVCT) for 
malignant hyperthermia (MH).  A total of 432 patients were included in the study: 186 
cases of IIM and 246 cases of non-inflammatory myopathies (NIM) and other 
neuromuscular disorders. In addition, 20 biopsies from individuals undergoing 
investigation for suspected MH, who were MH-negative on the IVCT and had normal 
muscle histology, comprised the normal control group. The IIM cases included: 
sporadic inclusion body myositis (s-IBM) 42; dermatomyositis (DM) 33; polymyositis 
(PM) 12; overlap syndromes 16; immune-mediated necrotising myopathy (IMNM) 16; 
focal myositis 15; granulomatous myositis 7; unclassified myositis 45 (Figure 1, Tables 
3 & 4). The final diagnosis of IIM was based on a combination of clinical and 
histopathological findings, as well as the subsequent clinical course and response to 
treatment [2]. In the case of IBM all patients fulfilled the clinical and histopathologic 
criteria for definite IBM according to Griggs et al [20] and the 2011 proposed ENMC 
criteria for clinicopathologically defined IBM [21]. 
 
The NIM group included: muscular dystrophies and distal myopathies 37; non-immune 
mediated necrotising myopathies 36; metabolic myopathies 20; non-specific 
myopathies 93; neurogenic disorders 46; other muscle disorders 14. Details of the 
cases of necrotising myopathy, muscular dystrophies and distal myopathies are given 
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in Table 3. The mean (±sd) ages were 59.1±16.1 years in the IIM and 51.9±21.5 years in 
NIM group. Further details of the age ranges of the different subgroups are provided in 
Table 4. 
 
2.2 Immunohistochemistry techniques 
Needle or open muscle biopsies were mainly from the vastus lateralis, deltoid or 
gastrocnemius muscles. The muscle tissue was routinely frozen in isopentane cooled 
with liquid nitrogen and stored at -70°C. Routine staining techniques included 
haematoxylin and eosin (H&E), modified Gomori trichrome and enzyme histochemistry 
for mitochondria (NADH, SDH and cytochrome c oxidase). Immunoperoxidase stains 
for MHC-I and II and C5b-9 (membrane attack complex of complement) and CD31 were 
performed on 8-µm acetone fixed cryostat sections using the streptavidin–biotin 
complex technique with diaminobenzidine as a colour indicator. Immunostaining for T- 
and B-cell subsets was performed on paraffin sections using the streptavidin–biotin 
complex technique. For MHC-I, the antibody used was a monoclonal mouse anti-
human HLA Class 1 antigen clone W6/32 (DAKO-HLA-ABC) code number M 0736 DAKO, 
Denmark A/S isotype IgG2a kappa  in a dilution of 1:200. For MHC-II, a monoclonal 
mouse anti-HLA-DR, which recognises a human MHC class II antigen and is composed 
of mouse isotype IgG2a heavy chains and kappa light chains, clone HLA-DR (L246), 
code no 347360, Becton Dickenson Biosciences, San Jose, was used in a dilution of 
1:100. This antibody reacts with a non-polymorphic HLA-DR epitope and does not 
cross-react with HLA-DQ or HLA-DP. The irrelevant negative control antibody was a 
monoclonal mouse IgG2a composed of isotype IgG2a kappa, code number X0943 
DAKO Denmark A/S. The optimum titration was identified on the basis of the findings 
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in a preliminary study of 34 biopsies from cases of proven IIM and other myopathies to 
determine the highest dilution at which there was widespread strong staining of the 
sarcolemma and sarcoplasm consistent with the distribution previously reported in the 
literature.  The irrelevant control was then used at a similar immunoglobulin 
concentration of 1mg/l to the selected dilutions (0.9mg/l for W6/32 at 1 in 200 dilution 
and 0.25 mg/l for L246 at 1 in 100 dilution), corresponding to a dilution of 1 in 200.  As 
a positive comparative control, a CD31 monoclonal mouse anti-human endothelial 
blood vessel stain, clone JC70A, code M0823, DAKO, Denmark A/S was used to prevent 
over interpretation of the sarcolemma as being positive, and positive staining of blood 
vessel endothelial cells acted as an internal positive control.  
 
2.3 Interpretation of biopsies 
All biopsies were reported by an experienced myopathologist (VF or RCJ), who was not 
blinded, and were reviewed by an independent observer (FLM) if there was any 
uncertainty about the diagnosis. Inter-observer variability in reporting was not 
formally evaluated.  Biopsies were classified as showing definitely positive or negative 
staining, while biopsies with questionable or faint staining were considered as being 
negative.  Positive staining in necrotic or regenerating muscle fibres was not taken into 
account in the classification of biopsies. The patterns and distribution of sarcolemmal 
and sarcoplasmic staining in non-necrotic muscle fibres were interpreted qualitatively.  
Staining was classified as being ‘focal’ if it was present in single fibres or small groups 
of fibres only and ‘widespread’ if it was present in most or all the fibres in the biopsy. 
In addition, sarcolemmal staining was classified as being ‘complete’ or ‘incomplete’, 
depending on whether it involved the entire surface of muscle fibres or was patchy in 
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distribution. No attempt was made to grade the intensity of sarcolemmal or 
sarcoplasmic staining. 
 
2.4 Data Analysis 
Data were initially registered in a database (Microsoft Access 2010; Microsoft 
Corporation, Redmond, WA). The statistical analysis was done using SPSS V.15.0 
software (IBM, Armonk, NY). Sensitivity, specificity, predictive values and receiver 
operating characteristic (ROC) curves were used to test the discriminatory power of 
MHC-I and MHC-II staining in the diagnosis of IIM. Patterns of staining and presence of 
inflammatory infiltrates in the IIM and NIM groups were compared using the Chi 
square test for independence, the Fisher's exact test and the Z-test for proportions 
after adjusting the p-values with the Bonferroni correction. Logistic regression analysis 
was used to assess the relation to prior treatment and years from disease onset. P-
values <0.05 were considered statistically significant. 
 
3. Results 
 
3.1 Frequency of MHC-I and MHC-II staining 
There was no inflammation or MHC-I or MHC-II staining of muscle fibres in any of the 
normal control group of biopsies. The proportions of cases with positive staining for 
MHC-I and MHC-II individually, and of cases with negative staining in the different 
types of IIM and NIM are shown in Figures 2 & 3. MHC-II staining was less frequent 
than MHC-I staining and never occurred in the absence of MHC-I staining. Overall, the 
proportion of cases with positive MHC-I staining was 98.3% in the IIM group and 92.7% 
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in the NIM group, while MHC-II was positive in 61.7% and 10.1% respectively in the 
two groups (chi-square, χ²=125.8; p=0.000). There were no significant differences in 
the frequency of MHC-I positivity in the different IIM subgroups, whereas for MHC-II 
positivity, IBM stood out from the other groups with a MHC-II positivity of 100% (chi-
square, χ²=33.40, p=0.000), (Figure 4). When compared with the different IIM 
subgroups, the proportion of cases with negative MHC-II staining in the NIM group was 
significantly lower (Z-test; p<0.05). The proportion of MHC-I positive cases in the IIM 
group was not significantly different from that in the NIM group as a whole or in the 
dystrophies/distal myopathies, necrotising myopathies, non-specific myopathies or 
neurogenic subgroups, but was significantly higher than in the metabolic myopathy (Z-
test; p<0.05).  
 
The sensitivity, specificity and predictive values of positive MCH-I and MHC-II staining 
for the diagnosis of IIM are shown in Table 5. MHC-I showed a very high sensitivity 
(0.984) and low specificity (0.071), while MHC-II showed a high specificity (0.908) and 
moderate sensitivity (0.605). The ROC curves for the IIM group are shown in Figure 5. 
When only MHC-I staining was taken into consideration, the area under the curve was 
0.53 (standard error, SE: 0.28; p=0.215). The area increased to 0.762 (SE: 0.024; 
p<0.001) when MHC-II staining was added. In the absence of MHC-I staining, the ROC 
curve for MHC-II staining showed a similar area (0.754, SE: 0.025; p<0.001).  
 
3.2 Correlation with presence of inflammatory infiltrates 
Mononuclear inflammatory infiltrates were present in 147 biopsies (79.9%) in the IIM 
group and 43 biopsies (17.3%) in the NIM group (Table 6). In the IIM group there was 
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no association between MHC-I positivity and the presence of an inflammatory infiltrate 
(chi-square, χ²=0.591, p=0.446), whereas there was a significant association between 
MHC-II positivity and infiltrates (chi-square, χ²=6.041, p=0.014). In the NIM group 
there was no association between either MHC-I (Fisher's exact test, p=0.374) or MHC-II 
(chi-square, χ ²=3.255, p=0.071) positivity and the presence of inflammatory 
infiltrates. 
 
3.3 Patterns of MHC-I and MHC-II staining 
The patterns of staining in the IIM and NIM groups are summarised in Tables 7 & 8. 
Both focal and widespread patterns of sarcoplasmic and sarcolemmal MHC-I staining 
of non-necrotic fibres were found in both the IIM and NIM groups, but widespread 
staining was more frequent in the IIM group and focal staining was more frequent in 
the NIM group.  In the case of MHC-II, both widespread and focal patterns of staining 
were found in the IIM group, while in the NIM group positive MHC-II staining was 
infrequent, being present in only a small proportion of cases, and sarcolemmal staining 
was more often focal. A Chi-square test for independence showed that the IIM group 
had a more widespread and complete pattern of sarcolemmal expression for MHC-I 
and MHC-II than the NIM group and more frequent widespread sarcoplasmic staining.   
 
3.4 Correlation with disease duration and prior treatment 
In the IIM group, disease duration from onset of symptoms to muscle biopsy ranged 
from 0 to 30 years (2.0 ± 4.1 years). At the time of biopsy 63 patients were on 
treatment with prednisolone (44), or a combination of prednisolone and methotrexate 
or azathioprine (19). Logistic regression analysis showed that neither disease duration 
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nor absence of prior treatment were predictors of MHC-I positivity (χ²=3.57, p=0.167) 
and MHC-II positivity (χ²= 5.75, p=0.056). There was also a lack of correlation 
between the presence of inflammatory infiltrates and disease duration and prior 
treatment (χ²=4.060, p=0.131). 
 
4. Discussion 
 
The diagnosis of IIM has in the past been based largely on the criteria established by 
Bohan and Peter [22]. New diagnostic criteria have since been proposed [1,2,23,24] 
but muscle biopsy remains the most sensitive and specific diagnostic tool, as well as 
the most common cause of misdiagnosis due to misinterpretation [25]. The inclusion 
of immunohistochemical staining for MHC-I has been recommended for cases of 
suspected IIM to increase the degree of diagnostic certainty [2,23]. A number of 
previous studies have demonstrated a high sensitivity of up-regulated MHC-I 
expression in IIM biopsies, but relatively few studies have investigated the specificity 
of MHC-I staining compared to large numbers of control NIM biopsies, or have 
provided sufficient data to define the role of staining for MHC-II. In this study of the 
largest groups of IIM and NIM biopsies to date, we investigated the sensitivity and 
specificity of positive MHC-I and MHC-II staining and their combined value in 
distinguishing IIM from NIM biopsies. Our findings confirm that positive MHC-I staining 
has a high sensitivity in IIM, but indicate that its specificity for IIM is very low unless it 
is combined with positive MHC-II staining.  
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Expression of MHC-I in muscle fibres is associated with antigen processing and 
presentation and plays an integral part in the pathogenesis of the CD8+ T-cell 
mediated inflammatory myopathies PM and IBM [26]. However, recent studies have 
shown that MHC-I overexpression can also mediate muscle fibre damage and 
dysfunction even in the absence of inflammation, through non-immune mechanisms 
such as endoplasmic reticulum (ER) stress and induction of the unfolded protein 
response [11,26,27]. This could explain the incomplete efficacy of immunosuppressive 
drugs in the treatment of IIM and the disparity between the severity of muscle damage 
and extent of inflammatory infiltrates in muscle biopsies, as well as the increased 
MHC-I expression in non-inflammatory myopathies. The demonstration of MHC-I up-
regulation and its co-localisation with the ER marker calnexin in myositis biopsies has 
confirmed that MHC molecules can play a critical role in mediating ER stress by 
disrupting ER homeostasis [12,28]. Endoplasmic reticulum stress has also been 
associated with other conditions besides IIM such as myotonic dystrophy, 
dysferlinopathy, myasthenia gravis, statin-induced myopathy and metabolic 
myopathies [17,29–32]. It seems that ER stress mechanisms can activate inflammatory 
responses through a number of different pathways and mediators: e.g. NF-кB, JNK, 
reactive oxygen species, interleukin-6 and TNF-α [33,34]. Recent studies also suggest 
that immature muscle precursor cells are a possible source of type I interferon 
secretion and may be implicated in HLA class I overexpression through the activation 
of Toll-like Receptor 3 [35].  
 
The finding of upregulation of MHC-I expression in both the IIM and NIM groups may 
indicate that this is a secondary non-specific and common response to muscle damage 
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from various causes. However, our findings do not shed any light on whether the 
increased MHC-I expression may contribute to the muscle fibre injury per se in these 
conditions or is purely a downstream consequence of ER stress. The variable frequency 
and patterns of MHC-I immunostaining in IIM reported in the literature could be 
related to methodological differences, in particular variation in antibody dilution 
(Table 1), and in methods of detection and amplification.  Such differences may 
account for our finding of a higher frequency of MHC-I staining in the NIM group than 
in previous studies. The use of a more sensitive (low dilution) protocol could result in 
more widespread MHC-I staining, whereas with higher antibody dilutions, more 
restricted patchy or perifascicular patterns of staining might be found. A comparison of 
positive staining rates and staining patterns achieved in different centres using high 
and low antibody dilutions would be helpful in the standardisation of protocols for 
MHC immunohistochemical staining. Ultimately, an internationally accepted diagnostic 
standard based upon a level of sensitivity in terms of false negatives and false positives 
(for a defined level of strong MHC-I staining) for selected disease groups restricted not 
only to known IIMs and normal controls but also non-IIM disease controls is necessary 
to ensure that a “positive” result has equivalent diagnostic significance across multiple 
centres.   
 
In this study, we found a high specificity (0.891) and moderate sensitivity (0.605) for 
MHC-II expression in IIM and, as shown in Figure 5, the addition of MHC-II increases 
the diagnostic power of MHC staining in IIM. The diagnostic value of MHC-II has not 
been as well established as that of MHC-I. The literature shows inconsistent results, 
with some studies finding no expression of MHC-II on muscle fibres, while others 
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found positive expression with varying sensitivities (25%-93%) or specificity (100%) in 
IIM [7,36]. MHC-II expression is necessary to activate T-helper cells and to initiate an 
immune response, and muscle cells can act as facultative antigen-presenting cells 
through the expression of MHC-II molecules [19,37]. Their ability to process and 
present endogenous antigens via MHC-II molecules is believed to influence the 
perpetuation or spreading of muscle immune responses through a T-cell stimulatory 
function [38]. This was shown in sporadic IBM, where β-amyloid targeted for lysosomal 
degradation via autophagy was associated with MHC-II overexpression.[39] Recent 
findings suggest that TNF-α is one of the major immune regulators of macroautophagy 
in inflammatory myopathies, mediating MHC class II expression levels via the delivery 
of autophagosome contents to the cell surface [39]. Other proinflammatory molecules 
such as IL-1α, cathepsin S, IFN-γ, ICOS and ICOS-L have also been implicated in MHC-II 
expression [40–43]. The finding of high specificity of MHC-II expression for IIM may 
reflect the fact that immune responses dependent on MHC-II molecules do not have a 
major role in NIM. 
 
The independence of MHC expression in muscle fibres from the presence of adjacent 
inflammatory cell infiltrates has also been noted in previous studies [15,44–47]. This 
was observed in both the early and late chronic phases of the disease, and in 
symptomatic and asymptomatic muscles from the same individuals [48,49]. However, 
in the present study we found that, unlike MHC-I, there was a significant association 
between MHC-II expression and the presence of inflammatory infiltrates in the IIM 
group.  It is also well known that there is a poor correlation between clinical symptoms 
and the presence of inflammatory infiltrates in patients with myositis [15,43,50] 
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although clearance of infiltrates may correlate with clinical improvement after 
commencement of corticosteroid therapy [47]. The expression of cytokines such as IL-
1α has also been shown to be independent of inflammatory infiltrates or the state of 
evolution of the disease [15,49]. In addition, we found that the frequency of MHC 
expression was not affected by disease duration or prior treatment. A previous study 
also found that MHC overexpression was independent of disease duration and the 
degree of muscle damage, [51] while two other studies found that MHC-I expression 
was independent of corticosteroid therapy administered prior to the muscle biopsy 
and was not affected by the short-term use of immunosuppressive agents [9,52].  
 
In conclusion, our findings provide further evidence that MHC-I expression is non-
specific and appears to be a common response to muscle damage resulting from both 
immunological and non-immunological mechanisms such as ER stress. On the other 
hand, MHC-II expression has a high specificity for IIM, probably reflecting the fact that 
immune responses dependent on MHC-II molecules do not play a major role in NIM. 
Our findings indicate that combining immunohistochemical staining for MHC-I and 
MHC-II results in a greater degree of specificity for the diagnosis of IIM and suggest 
that both should be included routinely in the diagnostic evaluation of muscle biopsies 
from patients with suspected IIM, including cases with a clinical phenotype suggestive 
of IBM but lacking inflammation or other typical pathological changes. They also 
indicate that expression of both MHC-I and MHC-II may occur with a variety of 
pathological processes and cannot per se be regarded as an indicator of an immune-
mediated myopathy, or be interpreted in isolation without clinical and other 
pathological information. 
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FIGURES LEGENDS 
 
 
Figure 1: 
 
Title: Diagnostic categories and numbers of cases included in the study.  
Footnote: Sporadic inclusion body myositis (s-IBM); DM (dermatomyositis); PM 
(polymyositis); IMNM (Immune-mediated necrotising myopathies); MD & MD 
(muscular dystrophies and distal myopathies); NIMNM (non-immune mediated 
necrotising myopathies).  
 
Figure 2:  
 
Title: Proportions of cases with positive and negative staining for MHC-I and MHC-II in 
the idiopathic inflammatory myopathies group (IIM) and non-inflammatory 
myopathies group (NIM).  
Footnote: MHC-I + (blue); MHC-II + (green); MHC-I -, MHC-II - (light green) 
 
 
Figure 3: 
 
Title: Proportions of cases with positive and negative MHC-I and MHC-II staining in the 
idiopathic inflammatory myopathies group (IIM) and in the different subgroups of non-
inflammatory myopathies (NIM).  
Footnote: MHC-I + (blue); MHC-II + (green); MHC-I -, MHC-II - (light green). 
 
Figure 4:  
 
Title: Proportions of cases with positive and negative MHC-I and MHC-II staining in the 
different subgroups of the inflammatory myopathies.  
Footnote: Sporadic inclusion body myositis (s-IBM); polymyositis (PM); overlap 
syndromes (OS); dermatomyositis (DM); immune-mediated necrotising myopathies 
(IMNM); focal myositis (FM); unclassified myositis (UM). MHC-I + (blue); MHC-II + 
(green); MHC-I - and MHC-II - (light green) 
 
Figure 5: 
Title: Receiver operating characteristic (ROC) curves for positive MHC-I and MHC-II 
staining 
Footnote: MHC-I is shown in blue  (0.530, SE: 0.28; p=0.215) and MHC-II in green  
(0.754, SE: 0.025; p<0.001). The diagonal line in grey colour represents diagnosis by 
chance. The closer a ROC curve approaches the upper left corner of the diagram, the 
more discriminatory is the test. 
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Figure 1: Diagnostic categories and numbers of cases included in the study.  
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Figure 2:  Proportions of cases with positive and negative staining for MHC-I and MHC-II in the idiopathic inflammatory myopathies group (IIM) 
and non-inflammatory myopathies group (NIM).  
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Figure 3: Proportions of cases with positive and negative MHC-I and MHC-II staining in the idiopathic inflammatory myopathies group (IIM) and 
in the different subgroups of non-inflammatory myopathies (NIM).  
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Figure 4: Proportions of cases with positive and negative MHC-I and MHC-II staining in the different subgroups of the inflammatory 
myopathies.  
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Figure 5: Receiver operating characteristic (ROC) curves for positive MHC-I and MHC-II staining 
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Table 1: Summary of previous MHC immunohistochemical studies in idiopathic inflammatory myopathies. 
 
Ref Year n Conditions MHC-I +  MHC-II + MHC-I antibody, dilution MHC–II antibody, dilution 
[7] 2013  120 61PM, 14DM, 45IBM 100%  
100% IBM, 87% PM, 93% 
DM 
W6/32 (Dako, Glostrup, Denmark), NR CR3/43 (Dako), NR 
[8] 2012 18 14PM, 4 DM 94%-100% -  W6/32 (Dako Cytomation, Milan, Italy), 1:300 - 
[52] 2012 56 28DM, 28jDM 96% DM, 50% jDM 53.6% DM, 14.3% jDM Dakopatts (Glostrup, Denmark), 1:100 Dakopatts (Glostrup, Denmark), 1:100 
[33] 2010 13 5PM, 4IBM, 4DM 100% 100%  W6/32 (Dako), NR CR3/43 (Dako), NR 
[37] 2007 62 
20DM, 38PM, 3 IBM,  
1 sarcoidosis 
100% DM, 81.6% PM, 100 % 
IBM, 100% sarcoidosis 
20% DM, 23.7% PM, 66.6 % 
IBM, 100% sarcoidosis 
W6/32 (Dako), 1:50 TAL.1B5 (Dako), 1:40 
[54] 2008 15 7DM, 6PM, 2sIBM 100% - W6/32-HL (Novocastra, Newcastle, UK), 1:100 - 
[17] 2007 8 IMNM 100% 25%  W6/32 (Dako, Glostrup, Denmark), 1:600 L243 (Becton Dickinson, San Jose, CA), 1:100 
[50] 2006 11 8PM, 3DM 100% PM, 33% DM 87.5% PM, 0% DM W6/32 (Dako, Glostrup, Denmark), 1:3500 L243 (Becton Dickinson, San Jose, CA), 1:320 
[9] 2004 61 9DM, 23PM, 29 IBM 67% DM, 61% PM, 96% IBM - W6/32 (Dako, Carputeira, California, USA), 1:20 - 
[55] 2003 22 22DM, 5IBM, 1PM 100%  - B9.12.1 (Immunotech, Marseille, France), 1:200 - 
[56] 2003 15 15PM 100% 20% (Dako), NR  (Dako), NR 
[49] 2001 32 12DM, 20PM 100% DM, 85% PM 66% DM, 65% PM W6/32 (DAKO, Glostrup, Denmark), 1:3500 L243 (Becton Dickinson, San Jose, CA), 1:640 
[46] 1994 18 9PM, 7DM, 2IBM 
100% 
 
33% PM, 29% DM, 100% 
IBM 
B9.12.1 (Immunotech, Marseille, France),  NR L243 (Becton Dickinson, San Jose, CA), NR 
[57] 1989 19 6PM, 7IBM, 6DM 100% - 
W6/32 (Seralab, Crawley Down, Sussex, UK), 45-
0.018 µg/mL 
- 
[16] 1989 33 2DM, 23jDM 5PM, 3IBM 100% 0% 
W6/32 (Professor H. Festenstein, The London 
Hospital), NR 
L227/CA2 (Professor H. Festenstein, The London 
Hospital), NR 
[47] 1988 29 13DM, 2jDM, 7PM, 7IBM 
62% DM, 0% jDM, 100% 
PM, 100% IBM 
0% 
PHM4 (Cedarlene Laboratories, Hornby, Ontario), 
1:20 
CMD1 (Cedarlene Laboratories, Hornby, Ontario), 
1:20 
[58] 1988 15 15PM - 100% - M704 (Dako), 1:20 
[45] 1985 3 2DM, 1 acute myositis 100% - W6/32, 1:1 or undiluted - 
[59] 1985 13 8PM, 2DM, 1 MCTD - 100% - α-HLA-DR (Beckton Dickinson, Sunnyvale, CA), NR 
[60] 1983 13 12PM, 1DM 100% 92% 2A1, NR DA2, NR 
 
Footnote: DM: dermatomyositis; IBM: inclusion body myositis; jDM: juvenile dermatomyositis; MCTD: mixed connective tissue disease; MHC: major histocompatibility complex; NR: not reported; PM: polymyositis. 
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Table 2: Summary of previous MHC immunohistochemical studies of other muscle conditions. 
 
Ref Year n Conditions MHC-I +  MHC-II + MHC-I antibody, dilution MHC–II antibody, dilution 
[9] 2013 27 6N, 7MD, 8MC, 2CM, 2NS  44.4% 11.1% W6/32 (Dako, Glostrup, Denmark), NR CR3/43 (Dako), NR 
[10] 2012 46 
7 MC, 6MB, 5MD, 6HC, 
22MX 
43.5% approx. - W6/32 (Dako Cytomation, Milan, Italy), 1:300 - 
[52] 2012 56 4MD, 5MB 25% MD, 0% MB 0% Dakopatts (Glostrup, Denmark), 1:100 Dakopatts (Glostrup, Denmark), 1:100 
[32] 2010 13 4N, 10MG 70% MG, 0% N 30% MG, 0% N W6/32 (Dako), NR CR3/43 (Dako), NR 
[36] 2007 64 45MD, 5N, 3MB, 3CM, 8HC 11% 0% W6/32 (Dako), 1:50 TAL.1B5 (Dako), 1:40 
[54] 2008 15 20MD 0%  - W6/32-HL (Novocastra, Newcastle, UK), 1:100 - 
[11] 2004 163 
63MD, 6DM, 14MB, 6MC, 
11CM, 19N, 24MX, 20HC 
11% MD, 4% MX - W6/32 (Dako, Carputeira, California, USA), 1:20 - 
[56] 2003 18 18MD (10DYS, 8DMD) 70% DYS, 0% DMD 20% DYS, 0% DMD (Dako), NR  (Dako), NR 
[49] 2001 10 5 N, 5 MD 60% N, 60% MD 0% N, 0% MD W6/32 (DAKO, Glostrup, Denmark), 1:3500 L243 (Becton Dickinson, San Jose, CA), 1:640 
[57] 1989 16 6 MD, 6 HC 100% MD - 
W6/32 (Seralab, Crawley Down, Sussex, UK), 45-
0.018 µg/mL 
- 
[18] 1989 33 88MD, 22N 
MD (+++, ++, +/++, +),  
N (-/+) 
0% 
W6/32 (Professor H. Festenstein, The London 
Hospital), NR 
L227/CA2 (Professor H. Festenstein, The London 
Hospital), NR 
[47] 1988 29 7MD, 6N, 2MC, 1CM, 1MX 0% 0% 
PHM4 (Cedarlene Laboratories, Hornby, Ontario), 
1:20 
CMD1 (Cedarlene Laboratories, Hornby, Ontario), 
1:20 
[58] 1988 7 6MD, 1N - 0% - M704 (Dako), 1:20 
[45] 1985 26 21MD, 5N MD (++, +/++, -), N (-/+) - W6/32, 1:1 or undiluted - 
[60] 1983 7 7MD 100% 100% 2A1, NR DA2, NR 
CM: congenital myopathy; DMD: Duchenne muscular dystrophy; DM: distal myopathy; DYS: dysferlinopathy; HC: healthy control; MB: metabolic myopathy; MC: mitochondrial myopathy; MD: muscular dystrophy; 
MG: myasthenia gravis; MHC: major histocompatibility complex; MX: miscellaneous neuromuscular disorder; N: neurogenic disorder; NR: not reported; NS: non-specific myopathy.  
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Table 3: Details of the immune-mediated necrotising myopathies (IMNM), non-immune mediated necrotising myopathies (NIMNM), and 
muscular dystrophy / distal myopathy (MD & DM) subgroups and numbers of cases.  
 
Group Number of cases 
Immune-mediated necrotising myopathies (IMNM) 
Anti-HMGCR antibody positive 10 
Anti-SRP antibody positive  2 
Anti-Jo-1 antibody positive 1 
Anti-PM/Scl 75 antibody 1 
Anti-Ro52 antibody positive 1 
Paraneoplastic necrotising myopathy 1 
Non-immune mediated necrotising myopathies (NIMNM) 
Statin-induced necrotising myopathy 23 
Post-viral / post-infectious myopathy 3 
Indeterminate necrotising myopathy 10 
Muscular dystrophies and distal myopathies (MD & DM) 
Dystrophinopathy 13 
Facioscapulohumeral dystrophy (type I) 2 
Dysferlinopathy 8 
Calpainopathy 5 
Myotonic dystrophy (type I) 1 
Congenital dystrophy with rigid spine (SEPN1) 1 
Oculopharyngeal muscular dystrophy  1 
Infantile-onset LMNA-associated myopathy 1 
Indeterminate muscular dystrophy 5 
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Table 4:  Mean ages, standard deviations (SD) and age ranges for the different subgroups of cases included in the study 
 
Group Number of cases Mean age ± SD (years) Age range (years) 
s-IBM 42 66.6 ± 10.9 35-89 
DM 33 53.4 ± 15.2 21-75 
PM 12 62.5 ± 17.2 23-77 
Overlap syndrome 16 50.5 ± 14.5 28-77 
IMNM 16 64.6 ± 17.0 39-84 
Focal myositis 15 54.7 ± 11.9 37-82 
Granulomatous myositis 7 51.1 ± 16.7 27-66 
Unclassified myositis 45 58.9 ± 18.5 7-85 
Dystrophy/Distal myopathy 37 34.5 ± 23.6 1-76 
Metabolic myopathies 20 40.2 ± 25.8 1-89 
NIMNM 36 63.7 ± 16.1 6-87 
Neurogenic disorders 46 54.9 ± 22.2 1-86 
Non-specific myopathies 93 56.9 ± 15.4 16-86 
Other myopathies 14 39.1 ± 18.5 5-66 
Total 432 55.0 ± 19.7 1-89 
 
Footnote: S-IBM (sporadic inclusion body myositis); DM (dermatomyositis); PM (polymyositis); IMNM (immune-mediated necrotising 
myopathies); NIMNM (non-immune mediated necrotising myopathies). The ‘Other myopathies’ group included two cases of myofibrillar 
myopathy, which showed patchy low level MHC-I staining, but negative MHC-II staining. 
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Table 5: Sensitivity, specificity and predictive values of MHC-I and MHC-II for the diagnosis of IIM.  
 
 MHC-I SE CI (95%) MHC-II SE CI (95%) 
Sensitivity 0.984 0.009 0.983 ± 0.018 0.605 0.031 0.605 ± 0.061 
Specificity 0.071 0.016 0.057 ± 0.032 0.908 0.020 0.891 ± 0.039 
PPV 0.441 0.025 0.423 ± 0.048 0.818 0.033 0.781 ± 0.065 
NPV 0.864 0.073 0.833 ± 0.143 0.756 0.025 0.769 ± 0.049 
 
Footnote: SE: standard error; CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value  
 
 
 
 
Table 6: Proportion of MHC-I and MHC-II positive and negative cases in muscle biopsies with and without inflammatory infiltrates in the 
idiopathic inflammatory myopathies (IIM) and non-inflammatory myopathies (NIM) groups. 
 
 
Group IIM NIM  
Inflammatory Infiltrates Yes No Yes No 
Number of cases 147  39 43 203 
MHC-I + 145 (98.6%) 38 (97.4%) 41 (95.3%) 186 (91.6%) 
MHC-II + 96 (65.3%) 16 (41.0%) 8 (18.6%) 17 (8.4%) 
MHC-I - / MHC-II - 2 (1.4%) 1 (2.6%) 2 (4.7%) 17 (8.4%) 
Total 186 246 
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Table 7: Patterns of MHC-I and MHC-II staining in the idiopathic inflammatory myopathies (IIM) and non-inflammatory myopathies (NIM) 
groups.  
 
 
Footnote: Percentages indicate the proportions of cases with a particular staining pattern. Staining was classified as ‘focal’ if only single fibres 
or small groups of fibres were positively stained and ‘widespread’ if staining was present in most or all the fibres in the biopsy.  Sarcolemmal 
staining was classified as being ‘complete’ or ‘incomplete’, depending on whether it involved the entire surface of muscle fibres or was patchy 
in distribution. Differences between the IIM and NIM groups were tested using the chi-square test for independence.  
 
 
 
 
 Staining IIM NIM χ² p-value 
MHC-I 
 
 
Sarcolemmal 
Widespread Focal Negative Widespread Focal Negative   
89.0% 9.3% 1.7% 53.8% 38.9% 7.3% 58.9 0.000 
Complete Incomplete Negative Complete Incomplete Negative   
81.4% 16.9% 1.7% 63.3% 29.4% 7.3% 20.4 0.000 
Sarcoplasmic Widespread Focal Negative Widespread Focal Negative   
 73.9% 8.7% 17.4% 41.0% 9.5% 49.5% 76.9 0.000 
MHC-II 
 
 
Sarcolemmal 
 
 
Widespread Focal Negative Widespread Focal Negative   
25.7% 36.0% 38.3% 0.8% 9.3% 89.9% 148.0 0.000 
Complete Incomplete Negative Complete Incomplete Negative   
45.6% 15.8% 38.6% 4.8% 3.8% 91.4% 146.1 0.000 
Sarcoplasmic Widespread Focal Negative Widespread Focal Negative   
 29.1% 14.0% 56.9% 2.9% 1.4% 95.7% 99.8 0.000 
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Table 8: Patterns of MHC-I and MHC-II staining in the different groups of inflammatory myopathy.  
 
 
 
 
 
Footnote: Percentages refer to the proportion of cases with a particular staining pattern. s-IBM: sporadic inclusion body myositis; DM: 
dermatomyositis; PM: polymyositis; OS: overlap syndrome; IMNM: immune mediated necrotising myopathies; UM: unclassified myositis.  
 
 
 
  
   MHC-I staining MHC-II staining 
Group Number of cases Positivity 
Sarcolemmal Sarcoplasmic 
Positivity 
Sarcolemmal Sarcoplasmic 
Widespread Complete Widespread Widespread Complete Widespread 
s-IBM   42  100% 95.2% 83.3% 95.2% 100% 52.4% 69.0% 52.4% 
DM 33 97.0% 81.8% 87.9% 78.8% 54.5% 21.2% 45.5% 33.3% 
PM 12 100% 84.6% 61.5% 58.3% 69.2% 23.1% 58.3% 46.2% 
OS 16 100% 100% 87.5% 62.5% 56.3% 25.0% 43.8% 18.8% 
IMNM 16 100% 68.7% 75.0% 87.5% 43.7% 6.2% 21.4% 18.8% 
UM 45 100% 95.7% 87.0% 73.9% 47.8% 10.9% 34.8% 13.0% 
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• Positive MHC-I immunostaining has high sensitivity but low specificity 
• MHC-II positivity has greater specificity for the diagnosis of inflammatory myopathy 
• Positive MHC-II staining in biopsies with inflammation suggests immune-mediated myopathy 
• Both MHC-I and MHC-II staining should be included in the evaluation of inflammatory myopathy 
 
